Abbott Integrates Libre's Data with Epic's Electronic Health Record System, Providing Healthcare Professionals Seamless Glucose Monitoring Information

Rhea-AI Summary

Abbott has partnered with Epic to integrate data from its FreeStyle Libre continuous glucose monitoring (CGM) systems directly into Epic's electronic health record systems in the U.S. This first-of-its-kind integration allows data from users' LibreView accounts to automatically link to Epic's platform.

Through Epic's Aura software, over 575,000 U.S. healthcare providers serving 280 million patients will gain streamlined access to patients' glucose data within their existing workflows. The collaboration aims to enhance care efficiency by enabling providers to view glucose data before, during, and after patient consultations.

Key benefits include:

• Improved workflow efficiency for healthcare providers
• Seamless access to CGM data in patient charts
• Enhanced patient-provider collaboration
• More time for care management versus administrative tasks

Abbott plans to expand this model to other medical devices and connected care platforms in the future. Healthcare providers interested in updates can contact Abbott at Libre.Epic@abbott.com.

Positive

• Integration with Epic's system gives Abbott access to 280 million U.S. patients through 575,000 healthcare providers
• First-mover advantage as the first medical device integration with Epic, with potential for expanding to other Abbott devices
• Strengthens market leadership position in CGM technology
• Creates operational efficiency for healthcare providers, potentially driving higher adoption of Libre systems
• Opens pathway for future integration of other Abbott medical devices and connected care platforms

Negative

• None.

Insights

Medical Technology Analyst

Abbott's Epic integration extends Libre CGM's ecosystem reach to 575,000+ providers, enhancing its market-leading position in diabetes care technology.

Abbott's integration of its FreeStyle Libre continuous glucose monitoring (CGM) systems with Epic's electronic health records represents a strategic enhancement to its diabetes care ecosystem. This first-of-its-kind agreement connects Abbott's world-leading CGM technology directly to one of healthcare's dominant EHR platforms.

The integration creates a seamless data flow between Libre users' LibreView accounts and the Epic system, enabling 575,000+ U.S. healthcare providers serving 280 million patients to access glucose data directly within their clinical workflows. By reducing friction in data access, Abbott strengthens the Libre platform's utility within the clinical setting.

This partnership addresses a significant pain point in diabetes care – fragmented data access. Clinicians typically need to navigate multiple systems during patient consultations, creating inefficiencies. With integrated data access before, during, and after patient meetings, providers can focus more on care management and less on administrative tasks.

Notably, Abbott frames this as just the first step in a broader connected care strategy, indicating plans to expand this integration model to other medical devices and connected care platforms. This suggests Abbott is pursuing a comprehensive approach to medical device data integration that extends beyond diabetes care.

Healthcare IT Expert

Epic integration positions Abbott's Libre data within clinical workflows, addressing healthcare's data fragmentation challenges while enhancing care coordination.

This integration between Abbott and Epic represents a meaningful advance in healthcare interoperability. By connecting Libre CGM data directly with Epic's EHR through Epic's Aura software, Abbott addresses one of healthcare's persistent challenges: siloed data systems that create barriers to comprehensive patient care.

The healthcare value proposition is clear – clinicians gain effortless access to glucose monitoring data within their existing workflows. This seamless data access enables more informed clinical decision-making without requiring providers to log into separate platforms or manually transfer information.

For healthcare organizations using Epic (which represents a substantial portion of the U.S. healthcare market), this integration reduces implementation barriers for Abbott's technology. The ability to view glucose data before, during, and after patient meetings creates opportunities for more proactive care management approaches in diabetes treatment.

From a healthcare IT architecture perspective, this partnership leverages Epic's Aura platform, which is designed specifically to connect health systems with diagnostic labs and device manufacturers. By utilizing this established integration framework, Abbott potentially simplifies the technical implementation process for healthcare organizations while maintaining data security and workflow integrity.

• Collaboration brings together FreeStyle Libre^® Systems, the world's leading continuous glucose monitoring technology (CGM)¹ with Epic, a healthcare software company, to streamline access to CGM data for healthcare organizations
• Integration empowers U.S. clinicians to enhance patient care by incorporating Libre's data directly into their workflows

ABBOTT PARK, Ill., April 29, 2025 /PRNewswire/ -- Abbott (NYSE: ABT), the global leader in continuous glucose monitoring (CGM) biowearable technology¹, today announced that it has entered a first-of-its-kind agreement to integrate data from its world-leading¹ Libre CGM systems directly into Epic's electronic health record systems in the U.S. The collaboration aims to improve workflow efficiency for providers through Epic's Aura software, which brings health systems together with diagnostics labs and medical device manufacturers.

Through this integration, data from a user's LibreView† account can be automatically linked to Epic, allowing clinicians to effortlessly view their patients' glucose data within Epic before, during and after meeting with their patients. This seamless process ensures healthcare providers can access key glucose data directly within their preferred workflows, enabling more informed care.

"Our goal is to simplify care and drive better outcomes for both providers and patients," said Lisa Earnhardt, executive vice president and group president of medical devices for Abbott. "While the integration with Libre data is Abbott's first medical device offering with Epic, it's just the beginning. We aim to expand this model to our other medical devices and connected care platforms in the future."

Now, more than 575,000 U.S. healthcare providers serving 280² million patients will have access to critical glucose data in their patients' charts, helping them spend less time finding data and more time on care management. With Libre systems and Epic, patients can more easily collaborate with their providers and utilize advanced CGM technology that can lead to improved patient engagement and behavior change^{* 3,4,5}.

"Our work with Abbott aims to make life simpler for the nearly 40 million people in the U.S. who live with diabetes today⁶," said Alan Hutchison, vice president at Epic. "Diabetes requires close collaboration between patients, primary care providers, and specialists to manage a complex and time-critical care plan. This will help everyone focus more on patient care and less on administrative hurdles."

Healthcare providers and health system administrations who would like to receive future updates on this integration can email Abbott's diabetes care business at Libre.Epic@abbott.com.

About FreeStyle Libre:
Abbott continues to pioneer ground-breaking technology to support people living with diabetes. The company revolutionized diabetes care 10 years ago with its world-leading FreeStyle Libre continuous glucose monitoring portfolio¹, which today is used by more than 7 million people across over 60 countries⁷. People use Libre technology to see their glucose numbers in real-time, providing insights into how food, activity, or insulin impacts their glucose to help them make progress on their health goals. There is full or partial reimbursement for Libre systems in more than 40 countries⁷.

About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.  

For important safety information, visit https://www.freestylelibre.us/safety-information.html

* Study was performed with the outside US version of the FreeStyle Libre 14 day system. Data is applicable to FreeStyle Libre 3 and 2 systems, as feature sets are similar as FreeStyle Libre 14 day system, excluding alarms.
†The LibreView data management software is intended for use by both patients and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis and evaluation of historical glucose meter data to support effective diabetes management. The LibreView software is not intended to provide treatment decisions or to be used as a substitute for professional healthcare advice.

1. Data on file, Abbott Diabetes Care. Based on the number of patients assigned to each manufacturer. 
2. According to data provided by Definitive Healthcare^TM and Epic.
3. Huang, Eileen, Mohamed Nada, and Eugene Wright, Jr. "73-LB: Ambulatory Glucose Profile Informs Better Treatment Decisions for Type 2 Basal-Insulin Patients." Diabetes 71, no. Supplement_1 (2022): 73–LB. https://doi.org/10.2337/db22-73-LB.
4. Haak, Thomas, et al. "Flash Glucose-sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-treated Type 2 Diabetes: a Multicentre, Open-label Randomised Controlled Trial." Diabetes Therapy 8, no. 1 (2017): 55–73. https://doi.org/10.1007/s13300-016-0223-6
5. Fokkert, Marion, et al. "Improved Well-Being and Decreased Disease Burden After 1-Year Use of Flash Glucose Monitoring (FLARE-NL4)." BMJ Open Diabetes Research and Care 7, no. 1 (2019): e000809. https://doi.org/10.1136/bmjdrc-2019-000809.
6. Centers for Disease Control and Prevention, National Diabetes Statistics Report, accessed April 11, 2025. https://www.cdc.gov/diabetes/php/data-research/index.html.   
7. Data on file, Abbott Diabetes Care. 

 

View original content:https://www.prnewswire.com/news-releases/abbott-integrates-libres-data-with-epics-electronic-health-record-system-providing-healthcare-professionals-seamless-glucose-monitoring-information-302440709.html

SOURCE Abbott

FAQ

How will Abbott's (ABT) integration with Epic's health records affect diabetes care?

Abbott's integration will allow 575,000+ US healthcare providers to directly access FreeStyle Libre CGM data within Epic's electronic health records, streamlining patient care and reducing administrative time. This affects care for potentially 280 million patients.

What is the market reach of Abbott's Libre CGM integration with Epic in 2025?

The integration reaches over 575,000 US healthcare providers serving 280 million patients, making glucose monitoring data from Abbott's FreeStyle Libre system directly accessible within Epic's electronic health records.

How does Abbott's (ABT) LibreView data sharing work with Epic's system?

Data from a patient's LibreView account automatically links to Epic's system, allowing healthcare providers to view glucose data before, during, and after patient meetings within their existing workflow.

Will Abbott (ABT) expand its Epic integration beyond FreeStyle Libre?

Yes, according to Abbott's executive VP Lisa Earnhardt, while Libre data integration is their first medical device offering with Epic, they plan to expand this model to other medical devices and connected care platforms.

How many diabetes patients could benefit from Abbott's Epic integration?

The integration could potentially benefit nearly 40 million people in the US living with diabetes by enabling closer collaboration between patients, primary care providers, and specialists.